The Danish drugmaker said at the time that because of the manufacturing issue, it didn't expect to be able to meet demand for the drug in the U.S. during the first half of 2022. A Novo Nordisk spokesperson confirmed over the weekend that "the contract manufacturer referred to in the Dec 17 Company Announcement is Catalent." On its website, Catalent says its Brussels facility stands at 265,287 square feet, about the size of four and a half football fields.